# Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

> **NCT04536077** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 16 (actual)

## Conditions studied

- Pancreatic Cancer
- Cancer of the Pancreas
- Pancreas Cancer

## Interventions

- **DRUG:** CDX-301
- **DRUG:** CDX-1140
- **PROCEDURE:** Research blood draw

## Key facts

- **NCT ID:** NCT04536077
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-13
- **Primary completion:** 2023-11-21
- **Final completion:** 2023-11-21
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Celldex decision
- **Last updated:** 2024-10-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04536077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04536077, "Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04536077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*